Monday, June 7, 2021

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), PayPal Holdings (PYPL), and Thermo Fisher Scientific (TMO). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of JPMorgan have outperformed the Zacks Major Regional Banks industry in the last one-year period (+51.4% vs. +47.2%). The Zacks analyst believes that branch openings in new regions, inorganic expansion strategies and strong mortgage banking business are expected to keep aiding financials in the upcoming quarters.

While the Fed's accommodative policy and near-zero rates are likely to hamper interest income and margins, a robust economic recovery will likely lead to rise in demand for loans. Furthermore, JPMorgan's impressive capital deployments reflect earnings strength and a solid balance sheet.

(You can read the full research report on JPMorgan here >>>)

PayPal shares have gained +21.2% over the last six months against the Zacks Internet Software industry’s loss of -11.7%. The Zacks analyst believes that PayPal is benefiting from robust growth in total payments volume owing to increasing net new active accounts.

Further, Venmo’s improving monetization efforts and rising adoption rate across various platforms are aiding the total active accounts growth. Additionally, solid momentum of core peer to peer and PayPal Checkout experiences is a tailwind. Also, accelerating transaction revenues are likely to continue driving revenues.

(You can read the full research report on PayPal here >>>)

Shares of Thermo Fisher have gained +2% in the past three months against the Zacks Medical Instruments industry’s gain of +2.5%. The Zacks analyst believes that with several takeovers including Advanced Bioprocessing buyout from BD and Patheon, Thermo Fisher is expanding inorganic growth profile.

In terms of end market, pharma and biotech registered growth on robust performance in bioproduction and pharma services. However, the pandemic has massively disrupted the global supply chain. Foreign currency fluctuations and a competitive landscape are other major downsides.

(You can read the full research report on Thermo Fisher here >>>)

Other noteworthy reports we are featuring today include PepsiCo (PEP), McDonald's (MCD) and Canadian National Railway Company (CNI).

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Sheraz Mian

Director of Research

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>